000272509 001__ 272509
000272509 005__ 20250127091515.0
000272509 0247_ $$2pmc$$apmc:PMC11681444
000272509 0247_ $$2doi$$a10.1161/JAHA.124.036054
000272509 0247_ $$2altmetric$$aaltmetric:168836211
000272509 0247_ $$2pmid$$apmid:39319465
000272509 037__ $$aDZNE-2024-01185
000272509 041__ $$aEnglish
000272509 082__ $$a610
000272509 1001_ $$0P:(DE-2719)9002544$$aNacarkucuk, Efe$$b0$$eFirst author
000272509 245__ $$aNeuroprotective Effect of Melatonin in a Neonatal Hypoxia–Ischemia Rat Model Is Regulated by the AMPK/mTOR Pathway
000272509 260__ $$aNew York, NY$$bAssociation$$c2024
000272509 3367_ $$2DRIVER$$aarticle
000272509 3367_ $$2DataCite$$aOutput Types/Journal article
000272509 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1729167939_2185
000272509 3367_ $$2BibTeX$$aARTICLE
000272509 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000272509 3367_ $$00$$2EndNote$$aJournal Article
000272509 520__ $$a Melatonin has been shown to be neuroprotective in different animal models of neonatal hypoxic-ischemic brain injury. However, its exact molecular mechanism of action remains unknown. Our aim was to prove melatonin's short- and long-term neuroprotection and investigate its role on the AMPK (AMP-activated protein kinase)/mTOR (mammalian target of rapamycin) pathway following neonatal hypoxic-ischemic brain injury.Seven-day-old Wistar rat pups were exposed to hypoxia-ischemia, followed by melatonin or vehicle treatment. Detailed analysis of the AMPK/mTOR/autophagy pathway, short- and long-term neuroprotection, myelination, and oligodendrogenesis was performed at different time points. At 7 days after hypoxia-ischemia, melatonin-treated animals showed a significant decrease in tissue loss, increased oligodendrogenesis, and myelination. Long-term neurobehavioral results showed significant motor improvement following melatonin treatment. Molecular pathway analysis showed a decrease in the AMPK expression, with a significant increase at mTOR's downstream substrates, and a significant decrease at the autophagy marker levels in the melatonin group compared with the vehicle group.Melatonin treatment reduced brain area loss and promoted oligodendrogenesis with a clear improvement of motor function. We found that melatonin associated neuroprotection is regulated via the AMPK/mTOR/autophagy pathway. Considering the beneficial effects of melatonin and the results of our study, melatonin seems to be an optimal candidate for the treatment of newborns with hypoxic-ischemic brain injury in high- as well as in low- and middle-income countries.
000272509 536__ $$0G:(DE-HGF)POF4-352$$a352 - Disease Mechanisms (POF4-352)$$cPOF4-352$$fPOF IV$$x0
000272509 588__ $$aDataset connected to CrossRef, Journals: pub.dzne.de
000272509 650_7 $$2Other$$aAMPK/mTOR/autophagy
000272509 650_7 $$2Other$$amelatonin
000272509 650_7 $$2Other$$aneonatal hypoxia–ischemia
000272509 650_7 $$2Other$$aneuroprotection
000272509 650_7 $$2Other$$arat
000272509 650_7 $$0JL5DK93RCL$$2NLM Chemicals$$aMelatonin
000272509 650_7 $$0EC 2.7.11.1$$2NLM Chemicals$$aTOR Serine-Threonine Kinases
000272509 650_7 $$2NLM Chemicals$$aNeuroprotective Agents
000272509 650_7 $$0EC 2.7.1.1$$2NLM Chemicals$$amTOR protein, rat
000272509 650_7 $$0EC 2.7.11.31$$2NLM Chemicals$$aAMP-Activated Protein Kinases
000272509 650_2 $$2MeSH$$aAnimals
000272509 650_2 $$2MeSH$$aMelatonin: pharmacology
000272509 650_2 $$2MeSH$$aHypoxia-Ischemia, Brain: metabolism
000272509 650_2 $$2MeSH$$aHypoxia-Ischemia, Brain: drug therapy
000272509 650_2 $$2MeSH$$aHypoxia-Ischemia, Brain: pathology
000272509 650_2 $$2MeSH$$aTOR Serine-Threonine Kinases: metabolism
000272509 650_2 $$2MeSH$$aAnimals, Newborn
000272509 650_2 $$2MeSH$$aRats, Wistar
000272509 650_2 $$2MeSH$$aNeuroprotective Agents: pharmacology
000272509 650_2 $$2MeSH$$aDisease Models, Animal
000272509 650_2 $$2MeSH$$aSignal Transduction: drug effects
000272509 650_2 $$2MeSH$$aAMP-Activated Protein Kinases: metabolism
000272509 650_2 $$2MeSH$$aAMP-Activated Protein Kinases: drug effects
000272509 650_2 $$2MeSH$$aAutophagy: drug effects
000272509 650_2 $$2MeSH$$aOligodendroglia: drug effects
000272509 650_2 $$2MeSH$$aOligodendroglia: metabolism
000272509 650_2 $$2MeSH$$aOligodendroglia: pathology
000272509 650_2 $$2MeSH$$aBrain: drug effects
000272509 650_2 $$2MeSH$$aBrain: metabolism
000272509 650_2 $$2MeSH$$aBrain: pathology
000272509 650_2 $$2MeSH$$aRats
000272509 650_2 $$2MeSH$$aBehavior, Animal: drug effects
000272509 7001_ $$0P:(DE-2719)2810557$$aBernis, Maria E.$$b1$$udzne
000272509 7001_ $$0P:(DE-2719)9001591$$aBremer, Anna-Sophie$$b2$$udzne
000272509 7001_ $$0P:(DE-2719)9003296$$aGrzelak, Kora$$b3$$udzne
000272509 7001_ $$0P:(DE-2719)9000835$$aZweyer, Margit$$b4
000272509 7001_ $$0P:(DE-2719)9001055$$aMaes, Elke$$b5$$udzne
000272509 7001_ $$0P:(DE-2719)9002524$$aBurkard, Hannah$$b6$$udzne
000272509 7001_ $$0P:(DE-2719)9000732$$aSabir, Hemmen$$b7$$eLast author$$udzne
000272509 773__ $$0PERI:(DE-600)2653953-6$$a10.1161/JAHA.124.036054$$gVol. 13, no. 19, p. e036054$$n19$$pe036054$$tJournal of the American Heart Association$$v13$$x2047-9980$$y2024
000272509 8564_ $$uhttps://pub.dzne.de/record/272509/files/DZNE-2024-01185.pdf$$yOpenAccess
000272509 8564_ $$uhttps://pub.dzne.de/record/272509/files/DZNE-2024-01185.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000272509 909CO $$ooai:pub.dzne.de:272509$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000272509 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9002544$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000272509 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810557$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b1$$kDZNE
000272509 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001591$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b2$$kDZNE
000272509 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9003296$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b3$$kDZNE
000272509 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9000835$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b4$$kDZNE
000272509 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001055$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b5$$kDZNE
000272509 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9002524$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b6$$kDZNE
000272509 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9000732$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b7$$kDZNE
000272509 9131_ $$0G:(DE-HGF)POF4-352$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Mechanisms$$x0
000272509 9141_ $$y2024
000272509 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-29
000272509 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-08-29
000272509 915__ $$0LIC:(DE-HGF)CCBYNCND4$$2HGFVOC$$aCreative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND 4.0
000272509 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ AM HEART ASSOC : 2022$$d2023-08-29
000272509 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2022-11-30T16:55:33Z
000272509 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2022-11-30T16:55:33Z
000272509 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-08-29
000272509 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2023-08-29
000272509 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-29
000272509 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000272509 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2022-11-30T16:55:33Z
000272509 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2023-08-29
000272509 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bJ AM HEART ASSOC : 2022$$d2023-08-29
000272509 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-29
000272509 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-08-29
000272509 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-29
000272509 9201_ $$0I:(DE-2719)5000032$$kAG Sabir$$lNeonatal Neuroscience$$x0
000272509 9201_ $$0I:(DE-2719)1013032$$kAG Salomoni$$lNuclear Function in CNS Pathophysiology$$x1
000272509 980__ $$ajournal
000272509 980__ $$aVDB
000272509 980__ $$aUNRESTRICTED
000272509 980__ $$aI:(DE-2719)5000032
000272509 980__ $$aI:(DE-2719)1013032
000272509 9801_ $$aFullTexts